Sanofi-Aventis Removes Thimerosal From Adult Tetanus/Diphtheria Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Decavac will be priced at a 78% premium to the discontinued thimerosal-containing version of the vaccine due to additional manufacturing and packaging costs. The company is working with FDA to reduce or remove thimerosal from all its vaccine products.